Abstract
Takeda San Diego Inc is developing alogliptin, a small-molecule, orally available dipeptidyl peptidase IV (DPP IV) inhibitor, for the potential treatment of type 2 diabetes. In January 2008, Takeda announced that an NDA for alogliptin had been submitted to the FDA.
MeSH terms
-
Animals
-
Diabetes Mellitus, Type 2 / drug therapy*
-
Diabetes Mellitus, Type 2 / enzymology
-
Diabetes Mellitus, Type 2 / immunology
-
Dipeptidyl Peptidase 4 / metabolism
-
Dipeptidyl-Peptidase IV Inhibitors* / adverse effects
-
Dipeptidyl-Peptidase IV Inhibitors* / pharmacology
-
Dipeptidyl-Peptidase IV Inhibitors* / therapeutic use*
-
Drug Evaluation, Preclinical
-
Drug Interactions
-
Humans
-
Hypoglycemic Agents / adverse effects
-
Hypoglycemic Agents / pharmacokinetics
-
Hypoglycemic Agents / therapeutic use*
-
Molecular Structure
-
Patents as Topic
-
Piperidines / adverse effects
-
Piperidines / pharmacokinetics
-
Piperidines / therapeutic use*
-
Structure-Activity Relationship
-
Treatment Outcome
-
Uracil / adverse effects
-
Uracil / analogs & derivatives*
-
Uracil / pharmacokinetics
-
Uracil / therapeutic use
Substances
-
Dipeptidyl-Peptidase IV Inhibitors
-
Hypoglycemic Agents
-
Piperidines
-
Uracil
-
Dipeptidyl Peptidase 4
-
alogliptin